Trial Profile
A Phase I double-blind, placebo-controlled, single ascending dose study for LX-9211 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jun 2021
Price :
$35
*
At a glance
- Drugs LX 9211 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- 06 Jun 2021 Status has been changed to completed, as per Results published in the Clinical Therapeutics
- 06 Jun 2021 Results from two phase1 SAD and MAD, evaluating safety, tolerability, and pharmacokinetics of orally administered LX9211 in healthy participants, published in the Clinical Therapeutics
- 18 Dec 2018 Results published in the Media Release